One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Adjuvant ado-trastuzumab emtansine improved ... “Prior to [the KATHERINE trial], HER2-directed drug treatments for early breast cancer were administered either before or after surgery since ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...

A study finds that celecoxib improves disease-free survival in stage 3 colon cancer patients with positive ctDNA after ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

T-DM1 is an antibody-drug conjugate that combines trastuzumab ... After surgery, patients were randomly assigned to receive adjuvant standard trastuzumab or T-DM1. At 7-years follow up, invasive ...